🇺🇸 scopolamine patch in United States

86 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 86

Most-reported reactions

1. Nausea — 19 reports (22.09%)
2. Vomiting — 16 reports (18.6%)
3. Dizziness — 11 reports (12.79%)
4. Headache — 9 reports (10.47%)
5. Dehydration — 7 reports (8.14%)
6. Fatigue — 6 reports (6.98%)
7. Death — 5 reports (5.81%)
8. Feeling Abnormal — 5 reports (5.81%)
9. Anxiety — 4 reports (4.65%)
10. Confusional State — 4 reports (4.65%)

Source database →

Frequently asked questions

Is scopolamine patch approved in United States?

scopolamine patch does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for scopolamine patch in United States?

Rutgers, The State University of New Jersey is the originator. The local marketing authorisation holder may differ — check the official source linked above.